Post

New research · Ophthalmology
Investigative ophthalmology & visual science · 5d
Randomized trialInvestigative ophthalmology & visual science · 2026

A Topographical Analysis of Visual Field Improvement in a Phase 2 Randomized Trial of Nicotinamide and Pyruvate for Open-Angle Glaucoma.

C Gustavo De Moraes, Aakriti G Shukla, George A Cioffi … Jeffrey M Liebmann
Read paper
OphthalmologyRandomized trial

Nicotinamide plus pyruvate increased odds of localized visual field improvement in glaucoma

A Topographical Analysis of Visual Field Improvement in a Phase 2 Randomized Trial of Nicotinamide and Pyruvate for Open-Angle Glaucoma.

C Gustavo De Moraes … Jeffrey M Liebmann
Investigative ophthalmology & visual science · 2026
Purpose

The purpose of this study was to characterize topographical visual field (visual field) improvement using pointwise total deviation (total deviation) slopes referenced to baseline severity, and to evaluate structure-function and cognitive associations in eyes receiving nicotinamide and pyruvate (NAM + PYR) treatment versus placebo.

Methods

This post hoc analysis used study-eye data from a phase 2 randomized trial of nicotinamide (3 g/day) plus pyruvate (3 g/day) versus placebo in open-angle glaucoma, with four baseline and four post-baseline visual field visits.

Results

treated eyes were nearly 4 times more likely to show improved vision than untreated eyes

OR 3.73 (95% CI 2.36 to 5.89)
null = 12.365.89
CI excludes the null - significant
More results

Improvement clustered along arcuate pathways and within moderate-to-deep baseline damage.

The Bayesian model estimated a 98.4% posterior probability that NAM + PYR treatment increased improving locations; retinal nerve fiber layer priors corroborated modestly but did not materially refine inference.

More results

No association was found with Montreal Cognitive Assessment scores.

“
Conclusion · 1 of 2

Topographical, slope-based endpoints reveal localized arcuate visual field improvement with nicotinamide and pyruvate that is missed by global indices and not explained by cognitive change.

Conclusion · 2 of 2

Bayesian modeling suits small early-phase neuroprotection trials, although structural priors added little over this short follow-up.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment